Global Major Depressive Disorder (MDD) Drug Market Report 2021: Therapeutics Market Will Grow to $7.9B by 2029
April 19, 2021 07:58 ET
|
Research and Markets
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering. The MDD...
Antidepressants Market to Touch USD 18.29 Billion by 2027; Growing Awareness about Mental Health Conditions to Fuel the Market: Fortune Business Insights™
March 08, 2021 04:27 ET
|
Fortune Business Insights
Pune, India, March 08, 2021 (GLOBE NEWSWIRE) -- The global antidepressants market size is projected to reach USD 18.29 billion by 2027, exhibiting a CAGR of 2.9% during the forecast period. The...
Global Psychedelic Therapeutics Market Report 2020: Regulation, Toxicity Concerns, Procurement-Related Challenges and Perceptions Regarding Medical Use
October 14, 2020 04:59 ET
|
Research and Markets
Dublin, Oct. 14, 2020 (GLOBE NEWSWIRE) -- The "Global Psychedelic Therapeutics Market by Type of Psychedelic Substance, by Origin, by Type of Therapy, by Route of Administration and by Key...
Anxiety Disorder and Depression Treatment Market To Reach USD 18.90 Billion By 2026 | Reports And Data
May 15, 2019 13:27 ET
|
Reports And Data
The rise in the graying population and minimal side effects associated with the treatment are some of the factors boosting the market for Anxiety Disorder and Depression Treatment. Market Size – USD...
CCHR Florida Hosts Open House for Self-Harm Awareness Month
March 06, 2019 19:25 ET
|
Church of Scientology Flag Service Organization
CLEARWATER, Fla., March 06, 2019 (GLOBE NEWSWIRE) -- In order to raise awareness on the subject of self-harm as well as suicide, the Florida chapter of the Citizens Commission on Human Rights...
Neuronetics, Inc. Raises $30 Million in Series E Financing
May 16, 2011 08:30 ET
|
Neuronetics
MALVERN, PA--(Marketwire - May 16, 2011) - Neuronetics, Inc., maker of the NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy® System for the treatment of major depression*, announced today...
New Trial Data Confirm Clinical Effectiveness and Good Adherence Rates With NeuroStar TMS Therapy in Patients With Major Depressive Disorder Treated in a Real World Practice Setting
May 15, 2011 19:00 ET
|
Neuronetics
HONOLULU, HI--(Marketwire - May 15, 2011) - Results of a Neuronetics-sponsored, multisite observational study of patients with major depressive disorder (MDD) treated with Neuronetics' NeuroStar...
Neuronetics Receives TiE50 Award for Technology Entrepreneurship
May 09, 2011 08:30 ET
|
Neuronetics
MALVERN, PA--(Marketwire - May 9, 2011) - Neuronetics, Inc., maker of the NeuroStar Transcranial Magnetic Stimulation (TMS) Therapy® System, has been selected by TiE Silicon Valley as a 2011 recipient...
New Data Show No Negative Long-Term Effect in Cognitive Function in Patients With Major Depressive Disorder Treated With NeuroStar TMS Therapy(R)
April 14, 2011 13:30 ET
|
Neuronetics
HONOLULU, HI--(Marketwire - Apr 14, 2011) - In an open-label study of patients with major depressive disorder (MDD) who had not benefitted from prior antidepressant medication and were treated with...
Neuronetics Appoints Vice President of Health Policy and Government Relations
March 02, 2011 08:00 ET
|
Neuronetics
MALVERN, PA--(Marketwire - March 2, 2011) - Neuronetics, Inc. today announced that Mary Hailey, an industry executive with more than 25 years of experience in designing and implementing healthcare...